FATE · Fate Therapeutics Inc

Track FATE — free

$2.65 +0.09 (+3.52%) At close · Aug 19

Market Cap

$319.32M

119.82M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 13, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +61%

above

Price vs 50-day avg +5%

above

RSI (14) 52

neutral

MACD trend Negative

52-week position 79%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +3%

trailing

6-month return +70%

trailing

YTD return +170%

this year

Relative strength +58%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $3 › 200d $2 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +31 funds added

Insider flow Distributing

Net -$203.5K over 90 days · 100% sells

Short interest Rising

6.41% of float · ▲ +5.0% MoM · 4.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

155 holders — mid 3-yr range

Squeeze score 62

elevated · 0–100

Fundamentals

Fair

Revenue growth −51%

Y/Y

EPS growth +30%

Y/Y

Free cash flow $-112.0M

Balance sheet $31.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 96%

annualized · 1-yr

Max drawdown −42%

past year

ATR 7.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Sep 30, 2023

full year

GAAP operating expenses GAAP $265M – $285M

year-end

Year-end cash and investments at least $300M

Prior guidance period ended · from the Earnings Call filed Mar 31, 2024

Cash and cash equivalents and investments · end of the year at least $270M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+61% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

52 Neutral

MACD trend

Negative Bearish

52-week position

79% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $3 › 200d $2 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +31 funds added

Insider flow Distributing

Net -$203.5K over 90 days · 100% sells

Short interest Rising

6.41% of float · ▲ +5.0% MoM · 4.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

155 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $3 · 79% Range high $3

vs 200-day avg +61% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash, cash equivalents, and investments	$205M	Full Year 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FATE Fate Therapeutics Inc this stock	$319.32M	+170.4%	-51.2%	—	6.4%
ONC BeOne Medicines Ltd.	$535.83B	+24.0%	+22179.2%	823.9	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.88B	+21.8%	+46.2%	30.8	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$84.27B	+8.9%	+20.8%	20.3	3.3%
ARGX Argenx SE	$61.75B	+22.8%	—	—	2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

155

% held: 60.0%
Net QoQ: -2.3M sh
Top holder: Redmile Group, LLC

Held Float

View

Held by Funds

Fund positions

132

View

Short & Settlement

Short Interest Rising

Shares short

7.7M

Days to cover: 4.6d
Change: +364.1K sh

View

Short Volume

Short vol %

28%

As of: Aug 19, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $5
As of: Jul 27, 2026

View

Off-Exchange

Off-exchange %

56.2%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$203.5K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jan 31, 2023

View

Financials

Revenue (FY)

$6.6M

Net income (FY): $-136.3M
EPS diluted: $-1.15

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 13, 2026
This year: 9

View

Proposed Sales

Value

$95.4K

Shares: 38.8K
Filed: Aug 4, 2026

View

Exempt Offerings

Offering

$50.0M

Filed: Jul 6, 2020

View

Earnings & Events

Earnings Calls

Last call

May 9, 2024

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
FATE	-2.6%	+2.7%	+69.9%	+8.2%	+170.4%
SPY	-0.4%	+2.9%	+11.6%	+3.0%	+12.8%
vs SPY	-2.1%	-0.2%	+58.3%	+5.2%	+157.6%

Key facts CIK 1434316 CUSIP 31189P102 13F (30d) 142 filings 141 filers Visit website Investor relations

FATE · Fate Therapeutics Inc

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance